Emerging treatments for pemphigoid diseases

Ralf J. Ludwig*, Kathrin Kalies, Jörg Köhl, Detlef Zillikens, Enno Schmidt

*Korrespondierende/r Autor/-in für diese Arbeit
32 Zitate (Scopus)

Abstract

Incidence of bullous pemphigoid (BP), the main pemphigoid disease, has increased over the past decades. Despite growing insights into pathogenic mechanisms, treatment is still based on systemic immunosuppression. Furthermore, overall mortality is significantly increased, which can be at least partially attributed to immunosuppressive therapy. Other pemphigoid diseases are also still difficult to treat. Hence, there is a so far unmet need for novel treatment options in patients with pemphigoid disease. Based on recent advances in understanding pathogenesis, several novel potential therapeutic targets have emerged. Interestingly, for some of these targets, lead compounds have been developed. Here, we review emerging therapeutic targets for pemphigoid diseases and discuss which compounds are likely be used in the future.

OriginalspracheEnglisch
ZeitschriftTrends in Molecular Medicine
Jahrgang19
Ausgabenummer8
Seiten (von - bis)501-512
Seitenumfang12
ISSN1471-4914
DOIs
PublikationsstatusVeröffentlicht - 01.08.2013

Fingerprint

Untersuchen Sie die Forschungsthemen von „Emerging treatments for pemphigoid diseases“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren